α-Tocopherol phosphate
Based on 8 publication(s) in Google Scholar
α-Tocopherol phosphate is an antioxidant that protects against long-wave UVA1 induced cell death and scavenge UVA1 induced ROS in a skin cell model. α-Tocopherol phosphate exhibits angiogenesis-promoting activity.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 38976-17-9
- Formula: C29H51O5P
- Molecular Weight:510.69
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-17589A
ChloroquineAntimalarial Agent -
HY-B0215
AcetylcysteineMucolytic Agent -
HY-N0729
Linoleic acidHuman Endogenous Metabolite -
HY-10182
LaduviglusibGSK-3 Inhibitor -
HY-15760
Necrostatin-1RIPK1 Inhibitor -
HY-N0196
BaicaleinXanthine Oxidase Inhibitor -
HY-15398
Vitamin D3Vitamin -
HY-100579
Ferrostatin-1Ferroptosis Inhibitor -
HY-13750
EbselenVDCC Inhibitor -
HY-111372
FinerenoneMineralocorticoid Receptor Antagonist
Publications Citing Use of MedChemExpress (MCE) α-Tocopherol phosphate
More- Cell Death Dis. 2022 Jan 21;13(1):73. [Abstract]
- Cell Death Discov. 2025 Aug 22;11(1):398. [Abstract]
- Cancer Cell Int. 2025 Dec 10. [Abstract]
- Appl Mater Today. 2021, 101066.
- Pharmacol Res Perspect. 2026 Feb;14(1):e70213. [Abstract]
- bioRxiv. 2025 Sep 9:2025.09.04.674327. [Abstract]
- Research Square Preprint. 2024 Dec 29.
- Nigerian Journal of Scientific Research. 18 (3): 2019.
Biological Activity
Description
In Vitro
α-Tocopherol phosphate (100 μM, 24 h) inhibits high Glucose (HY-B0389)/ischemic-induced apoptosis and migration in endothelial progenitor cells, promotes capillary-like tube formation through regulation of Bcl-2, Akt, NF-κB, p38MAPK and JNK expressions[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Endothelial progenitor cells derived from rat bone marrow
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Upregulated the expression of Bcl-2 and Akt.
Downregulated the expression of Tie2, Notch1, p38MAPK and JNK.
-
Cell Line:Endothelial progenitor cells derived from rat bone marrow
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Promoted the cell migration.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rats type 2 diabetes and ischemia models[2]
-
Dosage:100 μM α-Tocopherol phosphate incubated with EPCs
-
Administration:24 incubation, intramuscular injection of EPC into rats hind limbs
-
Result:Increased the capillary density of the ischemic hindlimbs.
Chemical Information
-
CAS No. 38976-17-9
-
Appearance Solid
-
Molecular Weight 510.69
-
Formula C29H51O5P
-
Color White to off-white
-
SMILES
CC1=C(O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CC2)C2=C(C)C(OP(O)(O)=O)=C1C
-
Synonyms
alpha-Tocopherol phosphate; TocP; vitamin E phosphate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Dis
RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m6A-dependent manner. [Abstract]2022 Jan 21;13(1):73. PMID: 35064112 -
Cell Death Discov
ERBB3 influences the ferroptosis pathway via modulation of lipid peroxidation and GSH synthesis in gastric cancer. [Abstract]2025 Aug 22;11(1):398. PMID: 40846695 -
Cancer Cell Int
Polysaccharides from Huaier induce autophagy-dependent ferroptosis to inhibit breast cancer stem cells in triple-negative breast cancer. [Abstract]2025 Dec 10. PMID: 41372887 -
-
Pharmacol Res Perspect
2026 Feb;14(1):e70213. PMID: 41445272 -
bioRxiv
Unravelling the anti-cancer mechanisms elicited by non-covalent thioredoxin reductase inhibitors for triple negative breast cancer therapy. [Abstract]2025 Sep 9:2025.09.04.674327. PMID: 40964317 -
-
Solvent & Solubility
In Vitro:
DMSO : ≥ 100 mg/mL (195.81 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Saleh MM, et al. The photoprotective properties of α-tocopherol phosphate against long-wave UVA1 (385 nm) radiation in keratinocytes in vitro. Sci Rep. 2021 Nov 17;11(1):22400. [Content Brief]
[2]. Wu Z, Zheng X, Meng L, et al. α-Tocopherol, especially α-tocopherol phosphate, exerts antiapoptotic and angiogenic effects on rat bone marrow-derived endothelial progenitor cells under high-glucose and hypoxia conditions. J Vasc Surg. 2018;67(4):1263-1273 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9581 mL | 9.7907 mL | 19.5814 mL | 48.9534 mL |
| 5 mM | 0.3916 mL | 1.9581 mL | 3.9163 mL | 9.7907 mL | |
| 10 mM | 0.1958 mL | 0.9791 mL | 1.9581 mL | 4.8953 mL | |
| 15 mM | 0.1305 mL | 0.6527 mL | 1.3054 mL | 3.2636 mL | |
| 20 mM | 0.0979 mL | 0.4895 mL | 0.9791 mL | 2.4477 mL | |
| 25 mM | 0.0783 mL | 0.3916 mL | 0.7833 mL | 1.9581 mL | |
| 30 mM | 0.0653 mL | 0.3264 mL | 0.6527 mL | 1.6318 mL | |
| 40 mM | 0.0490 mL | 0.2448 mL | 0.4895 mL | 1.2238 mL | |
| 50 mM | 0.0392 mL | 0.1958 mL | 0.3916 mL | 0.9791 mL | |
| 60 mM | 0.0326 mL | 0.1632 mL | 0.3264 mL | 0.8159 mL | |
| 80 mM | 0.0245 mL | 0.1224 mL | 0.2448 mL | 0.6119 mL | |
| 100 mM | 0.0196 mL | 0.0979 mL | 0.1958 mL | 0.4895 mL |
α-Tocopherol phosphate Related Classifications
HY-16686 Related Classifications
Powered by Bioz